1 reports of this reaction
2.6% of all ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HCL reports
#20 most reported adverse reaction
EYE PAIN is the #20 most commonly reported adverse reaction for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HCL, manufactured by Walgreen Company. There are 1 FDA adverse event reports linking ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HCL to EYE PAIN. This represents approximately 2.6% of all 38 adverse event reports for this drug.
Patients taking ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HCL who experience eye pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EYE PAIN is a less commonly reported adverse event for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HCL, but still significant enough to appear in the safety profile.
In addition to eye pain, the following adverse reactions have been reported for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HCL:
The following drugs have also been linked to eye pain in FDA adverse event reports:
EYE PAIN has been reported as an adverse event in 1 FDA reports for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
EYE PAIN accounts for approximately 2.6% of all adverse event reports for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HCL, making it a notable side effect.
If you experience eye pain while taking ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.